Introduction: Insulin secretory defects are a key feature in the pathophysiology of type 2
diabetes (T2D). Classical insulin-secreting agents such as sulfonlyureas stimulate insulin …

Oral antidiabetic sulfonylureas like tolbutamide and glyburide have been used to treat
patients with noninsulin dependent diabetes mellitus. These agents lower blood glucose by …

Clarification of the molecular mechanisms of insulin secretion is crucial for understanding
the pathogenesis and pathophysiology of diabetes and for development of novel therapeutic …

Defects in pancreatic islet β-cell function play a major role in the development of diabetes
mellitus. Type 1 diabetes is caused by a more or less rapid destruction of pancreatic β cells …

The worldwide population afflicted with diabetes is growing at an epidemic rate. There are
almost five times the number of people suffering from this disease today as compared to 10 …

Type 2 diabetes mellitus has become a world wide extended disease, and while insulin
insensitivity is an early phenomenon partly related to obesity, pancreas β-cell function …

A variety of compounds containing an imidazoline ring have the ability to stimulate insulin
secretion. Many of these also improve glycaemia in experimental models of type 2 diabetes …

Sulphonylureas have been used for over 50 years to enhance insulin secretion in patients
with Type II (non-insulin-dependent) diabetes mellitus but their therapeutic target was not …

The onset of type 2 diabetes is characterized by two determining factors: the insufficient
ability to secrete insulin and/or the resistance to its biological action. Although in a very small …

In Brief Impaired insulin secretion, increased hepatic glucose production, and decreased
peripheral glucose utilization are the core defects responsible for the development and …